| 2022 | A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatment | 문영철 | Article |
| 2011 | Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers | 문영철 | Meeting Abstract |
| 2021 | Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT | 문영철 | Article |
| 2008 | Final Report of "Korean Multicenter AML-2000 Trial": Intention to Treat Analysis Based on Cytogenctics Risk | 문영철 | Meeting Abstract |
| 2016 | Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study | 문영철 | Article |
| 2019 | Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy | 문영철 | Article |
| 2009 | Induction Therapy with "3+7" Chemotherapy Plus ATRA Followed by Consolidations with Three Courses of Idarubicin Alone and Maintenance Therapy with ATRA in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Has An Excellent Leukemia-Free Survival but Minimal Toxicity in Low and Intermediate Risk Groups | 성주명; 문영철 | Meeting Abstract |
| 2023 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | 문영철 | Article |
| 2022 | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia | 성주명; 문영철; 김대영; 박영훈 | Article |
| 2011 | Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation | 문영철 | Meeting Abstract |
| 2012 | Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement. | 문영철 | Meeting Abstract |
| 2012 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. | 문영철 | Meeting Abstract |
| 2011 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis | 문영철 | Meeting Abstract |
| 2021 | The 2020 revision of the guidelines for the management of myeloproliferative neoplasms | 문영철 | Review |
| 2007 | The clinical outcomes of autologous stem cell transplantation in peripheral T cell lymphoma: From retrospective Multicenter study in Korea. | 문영철 | Meeting Abstract |
| 2018 | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma | 문영철 | Article |
| 2010 | VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma | 정화순; 문영철 | Meeting Abstract |
